دوا کے تعاملات
Nivolumab + Thalidomide
شدت: شدید
Nivolumab and Thalidomide: major interaction.
آخری تازہ کاری ماخذ: UK SmPC
صرف صحت کے پیشہ ور افراد کے لیے — محض حوالے کے طور پر۔ یہ صفحہ مختصر خلاصہ ہے، طبی مشورہ نہیں، اور سرکاری لیبل یا طبی فیصلے کا متبادل نہیں۔ تجویز یا فراہمی سے پہلے ہمیشہ تصدیق کریں۔
اس صفحے کا طبی مواد صرف انگریزی میں دستیاب ہے۔
خلاصہ
Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
اس تعامل کا آسان لفظوں میں مطلب
Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Nivolumab belongs to Oncology; Thalidomide belongs to Miscellaneous.
ایسا کیوں ہوتا ہے
Combined immune modulation with PD-1 blockade and thalidomide analogs; the mechanism of excess harm is not fully established.
کیا کرنا ہے
Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
فارماسسٹ سے کیا پوچھیں
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ اراکین کے لیے
پورا صفحہ کھولیں
Nivolumab اور Thalidomide کے لیے مکمل طبی انتظام کی رہنمائی، اضافی نوٹس، شواہد کی تفصیل اور پورے نسخے کا تعامل چیکر کھولنے کے لیے اکاؤنٹ بنائیں اور Pro+ ٹرائل شروع کریں۔
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
ویب پر 7 دن تک Pro+ مفت آزمائیں۔ کارڈ کی ضرورت نہیں۔
حوالہ جات
- OPDIVO 10 mg/mL concentrate for solution for infusion - SmPC sections 4.3/4.5 (class statement: other immunosuppressants; "The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided because of their potential interferen") — electronic medicines compendium (UK SmPC)
Nivolumab کے دیگر تعاملات
Thalidomide کے دیگر تعاملات
اکثر پوچھے جانے والے سوالات
Can I take Nivolumab with Thalidomide?
MediHelp rates the interaction as major. Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
How serious is the interaction between Nivolumab and Thalidomide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Dexamethasone-tobramycin, Dexamethasone, Efgartigimod / hyaluronidase sc. The full list is on the Nivolumab page.
MediHelp ایپ میں مکمل مونوگراف، خوراک اور تعامل چیکر
MediHelp ایپ میں مکمل حوالہ کھولیں، متعدد ادویات کے تعاملات جانچیں اور خوراک کے ٹولز استعمال کریں۔
